biopharma-reporter2d
Eli Lilly reports positive phase 3 results for a weekly insulin formulation
New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, ...
biopharma-reporter2d
FDA lifts partial clinical hold on phase 3 low blood sugar treatment
Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a ...
biopharma-reporter2d
How modern trial designs propel cancer therapies to the market - interview
Clinical trials are becoming increasingly complex as emerging technologies such as immunotherapy enter the mainstream.
biopharma-reporter2d
FDA lifts partial clinical hold on phase 3 low blood sugar treatment
The partial clinical hold was placed on esodetug last year after historical data emerged showing liver toxicity in laboratory rats following treatment with the therapy. In May 2024, California-based ...
biopharma-reporter2d
FDA lifts partial clinical hold on phase 3 low blood sugar treatment
Rare disease biotech Rezolute recently announced that the FDA has lifted the partial clinical hold on RZ358 (ersodetug), a novel therapy in development for the treatment of low blood sugar ...